Home
Publishers
Categories
Trending
Inbox

Create Account
Sign in

- Nederlands
- Deutsch

Webinar: Navigating the rapidly evolving regulatory environment for gene and cell therapies

Fiercebiotech.com

Click here to subscribe to Fiercebiotech.com

Loading...

2 years ago

Html
Text

We’ll review the latest developments in the regulatory review process for gene and cell therapies

This week's Fierce Biotech is brought to you by Egnyte.

Webinar: Navigating the rapidly evolving regulatory environment for gene and cell therapies

Wednesday, March 9, 2022 | 2pm ET / 11am PT

In this webinar we’ll review the latest developments in the regulatory review process for gene and cell therapies, offering advice that companies can use to streamline their interactions with regulators, both in the U.S. and overseas.

Register To Save Your Spot

Topics include:

Understanding the FDA’s new guidance documents covering product development, accelerated approval pathways and other topics specific to gene and cell therapies. How to apply the lessons learned from Biomarin’s setback and other approval delays to improving development strategies for future gene and cell therapies. Comparing and contrasting the FDA’s policies for gene and cell therapies to those of regulatory bodies in other large global markets.

You are currently subscribed as newsletter@newslettercollector.com
If you no longer wish to receive promotions from Fierce Life Sciences, simply unsubscribe.
Refer to our Privacy Policy.
Fierce Life Sciences is a division of Questex LLC.
685 3rd Ave 21st Floor New York, NY 10017
© 2021 Questex LLC. All Rights Reserved.
Reproduction in whole or in part is prohibited without written permission.

Share on

Loading...

Other newsletters from Fiercebiotech.com

| 11.27.24 | Novartis plots field sales layoffs linked to Xolair, cancer combo; Trump picks Stanford economist to helm NIH Fiercebiotech.com
Last Wednesday at 19:26
| 11.27.24 | Trump names NIH pick; PTC axes ALS program, gains $150M in voucher sale Fiercebiotech.com
Last Wednesday at 17:10
| 11.26.24 | Amgen’s obesity data disappoint investo rs; Guardant awarded $292M in false advertising suit Fiercebiotech.com
Last Tuesday at 20:46

More newsletters from Fiercebiotech.com

Loading...

Related newsletters

© 2024

Information
Terms and Conditions
Privacy

Home
Publishers
Categories
Trending
Inbox

Create Account
Sign in

© 2024

Information
Terms and Conditions
Privacy

- Nederlands
- Deutsch